Zymeworks Stock Price, News & Analysis

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics for diseases including cancer, inflammation, and autoimmune disease, has announced its participation in four upcoming investor conferences in March 2025.

The company's management will attend the TD Cowen 45th Annual Health Care Conference in Boston on March 4, presenting at 10:30 am ET. They will also present at the Leerink Global Healthcare Conference in Miami on March 10 at 8:00 am ET.

Additionally, Zymeworks will participate in one-on-one meetings at the Barclays 27th Annual Global Healthcare Conference on March 11 and the Jefferies Biotech on the Beach Summit on March 12, both in Miami, FL.

Zymeworks Inc. (Nasdaq: ZYME) has appointed Oleg Nodelman to its board of directors, effective February 17, 2025. Nodelman, the Founder and Managing Director of EcoR1 Capital, , represents the largest current stockholder of Zymeworks and brings over two decades of investment management experience to the role.

This appointment marks the seventh new director added in the past two years as part of the company's board renewal process. Nodelman, who holds a Bachelor of Science in Foreign Service from Georgetown University, currently serves as a director at Galapagos NV and AnaptysBio. His expertise in business development, capital deployment, and deep connections in the biotech sector position him as a strategic addition to support Zymeworks' mission of developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, has scheduled its fourth quarter and full year 2024 financial results announcement for March 5, 2025, after market close.

The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day, where management will discuss the financial results and provide a corporate update. Investors can access the webcast live and replay through Zymeworks' investor relations website.

Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, has announced its participation in three major upcoming investor conferences in February 2025.

The company will be present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, participating in one-on-one meetings and a fireside chat at 11:20 am ET. Management will also join Citi's 2025 Virtual Oncology Leadership Summit for a virtual fireside chat on February 20 at 2:00 pm ET. Additionally, they will attend the B. Riley Securities Precision Oncology & Radiopharma Conference in New York on February 28, engaging in one-on-one meetings and a panel discussion.

Zymeworks (NASDAQ: ZYME) has outlined its strategic priorities for 2025-2026, highlighting significant developments in its pipeline. The company plans to submit IND applications for ZW220 and ZW251 in solid tumors in 2025, followed by ZW209 and ZW1528 in 2026. Phase 3 HERIZON-GEA-01 top-line results for Ziihera® in first-line HER2-positive gastroesophageal adenocarcinoma are expected in Q2-2025.

The company reported approximately $324 million in cash, cash equivalents, and marketable securities as of December 31, 2024. Combined with anticipated regulatory milestone payments, this provides a projected cash runway into the second half of 2027. Key 2024 achievements include FDA approval of Ziihera® for HER2-positive second-line BTC, initiation of first-in-human studies for ZW171 and ZW191, and completion of a $30 million share repurchase program.

Zymeworks (NASDAQ: ZYME) announced significant progress in its oncology programs and expansion into autoimmune and inflammatory diseases during its R&D Day. The company is ahead of schedule in delivering five Investigational New Drug (IND) applications for its solid tumor strategy, achieving this goal 18 months earlier than planned.

Key highlights include the nomination of ZW209, a novel trispecific T cell engager, as the fifth development candidate in their solid tumor portfolio, and ZW1528, their first development candidate for autoimmune and inflammatory diseases, targeting respiratory inflammation in COPD.

The company's pipeline focuses on gynecological, thoracic, and digestive system cancers, with five drug candidates expected to advance into clinical trials by first half of 2026. The expansion leverages their clinically validated Azymetric™ technology platform and expertise in multispecific therapeutics.

Zymeworks (Nasdaq: ZYME) has announced its participation in several upcoming investor conferences in December 2024 and January 2025. The company will attend the Piper Sandler Healthcare Conference, Citi's Global Healthcare Conference, Evercore HealthCONx Conference, and the J.P. Morgan Healthcare Conference.

Additionally, Zymeworks will host a Research & Development Day on December 12, 2024, in New York. Led by Chief Scientific Officer Paul Moore, the event will showcase updates on their solid tumor targeting antibody-drug conjugates and T-cell Engager molecules, announce a candidate nomination from their Trispecific TCE platform, and discuss potential expansion into hematological cancers and autoimmune diseases.

Zymeworks announces FDA accelerated approval of Ziihera (zanidatamab-hrii) for treating adults with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer. The approval is based on clinical trial results showing a 52% objective response rate and 14.9 months median duration of response. Ziihera becomes the first dual HER2-targeted bispecific antibody approved for this indication. The approval triggers a $25M milestone payment from Jazz Pharmaceuticals, with potential for up to $500M in additional regulatory milestones. Regulatory reviews are ongoing in China and Europe.

Zymeworks (NASDAQ: ZYME) has initiated dosing in a global Phase 1 clinical trial for ZW191, targeting folate receptor-⍺ (FR⍺) expressing advanced solid tumors. The trial (NCT06555744) will evaluate safety and tolerability in treating advanced ovarian, endometrial, and non-small cell lung cancers. The two-part study aims to enroll 145 adult patients across North America, Europe, and Asia-Pacific. ZW191 showed promising pre-clinical results with greater anti-tumor activity compared to benchmark in FR⍺-expressing tumor models. FR⍺ is present in approximately 75% of high-grade serous ovarian carcinomas and 70% of lung adenocarcinomas.